The use of dendritic cells for cancer vaccination

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 72-81

  Esche, Clemens ^a   Shurin, Michael R ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL COMMUNICATION; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS;

ANIMALIA;

EID: 0032910670     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 137:1142-1162. First report on DC.
2. Katz SI, Tamaki K, Sachs DH: Epidermal Langerhans cells are derived from cells originating In the bone marrow. Nature (1979) 282:324-326.
3. Volc-Platzer B, Stingl G, Wolff K, Hinterberger W, Schnedl W: Cytogenetic Identification of allogeneic epidermal Langerhans cells In a bone marrow-graft recipient. N Engl J Med (1984) 310:1123-1124.
4. Steinman RM: The dendritic cell system and its role in Immunologanlelty, Annu Rev Immunol (1991)9: 271-296. This marvelous review of DC a classic paper.
5. Peters JH, Ruhl S, Friedrichs D: Veiled accessory cells deduced from monocytes. Immunobiology (1987) 176:154-166.
6. Reid CD, Fryer PR, Clifford C, Kirk A, Tikerpae J, Knight SC: Identification of hematopoletic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) In human bone marrow and peripheral blood. Blood (1990) 76:1139-1149.
7. Chen LL, Adams JC, Steinman RM: Anatomy of germinal centers In mouse spleen, with special reference to "follicular dendritic cells". J Cell Biol (1978) 77:148-164.
8. Matsumoto M, Fu YX, Molina H, Huang G, Kim J, Thomas DA, Nahm MH, Chaplin DD: Distinct roles of lymphotoxln α and the type I tumor necrosis factor (TNF) receptor In the establishment of folllcular dendritic cells from none-bone marrow-derived cells. J Exp Med (1997) 186:1997-2004.
9. Liu YJ, Xu J, de Bouteiller O, Parham CL, Grouard G, Djossou O, de Saint-Vis B, Lebecque S, Banchereau J, Moore KW: Folllcular dendritic cells specifically express the long CR2/CD21 Isoform. J Exp Med (1997) 185:165-170.
10. Tew JG, Wu J, Qin D, Helm S, Burton GF, Szakal AK: Follicular dendritic cells and presentation of antigen and costimulatory signals to B-cells. Immunol Rev (1997) 156:39-52.
11. Lindhout E, Mevissen MLCM, Kwekkeboom J, Tager JM, Groot C: Direct evidence that human folllcular dendritic cells rescue germinal center B-cells from death by apoptosis. Clin Exp Immunol (1993) 91:330-336.
12. Ardavin C, Wu L, U CL, Shortman K: Thymic dendritic cells and T-cells develop simultaneously In the thymus from a common precursor population. Nature (1993) 362:761-763.
13. Marquez C, Trigueros C, Fernandez E, Toribio ML: The development of T-and non-T-cell lineages from CD34+ human thymc precursors can be traced by the differential expression of CD44. J Exp Med (1995) 181:475-483.
14. Galy A, Travis M, Cen D, Chen B: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity (1995) 3:459-473.
15. Saunders D, Lucas K, Ismaili J, Wu L, Maraskowsky E, Dunn D, Shortman K: Dendritic cell development In culture from thymic precursor cells In the absence of granulocyte-macrophage colony stimulating factor. J Exp Med (1996) 184:2185-2196. Lymphoid DC develop in the absence of GM-CSF and in the presence of IL-1, IL-3, IL-7, TNF, SCF and FL.
16. Sũss G, Shortman K: A subclass of dendritic cells kills CD4 T-cells via Fas/Fas-ligand-induced apoptosis. J Exp Med (1996) 183:1789-1796. FasL and lymphoid DC can induce apoptosis in CD4+ T-cells.
17. Ardavin C: Thymic dendritic cells. Immunol Today (1997) 18:350-361. Everthing you want to know about thymic DC
18. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol (1997)9:10-16.
19. Schuler G, Thumer B, Romani N: Dendritic cells: From Ignored cells to major players In T-cell-mediated Immunity. Int Arch Allergy Immunol (1997) 112:317-322.
20. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman R, Schuler G: Proliferating dendritic cell progenitors In human blood. J Exp Med (1994) 180:83-93.
21. Langerhans P: Über dië Nerven der menschlichen haut Virchows Arch (1868) 44:325-327.
22. Breathnach AS, Silver WK, Smith J, Heyner S: Langerhans cells in mouse skin experimentally deprived of Its neural crest components. J Invest Dermatol (1968) 50:147-160.
23. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252. A comprehensive review.
24. Birbeck MS, Breathnach AS, Everall JD: An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J Invest Dermatol (1961) 37:51-64.
25. Hart DNJ, Fuggle SV, Williams KA, Fabre JW, Ting A, Morris PJ: Localization of HLA-ABC and OR antigens in human kidney. Transplantation (1981) 31:428-433.
26. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kämpgen E, Romani N, Schuler G: High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med (1996) 184:741-746.
27. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol (1996) 24:859-862.
28. Steinman RM, Pack M, Inaba K: Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev (1997) 156:25-37.
29. Schwartz RH: A cell culture model for T-lymphocyte clonal anergy. Science (1990) 248:1349-1356.
30. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science (1970) 169:1042-1049.
31. Liu Y, Janeway CA: Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T-cells. Proc Nat Acad Sci USA (1992) 89:3845-3849.
32. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264:961-965.
33. Inaba K, Steinman RM, Witmer Pack M, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G: Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med (1992) 175:1157-1167. A new use for GM-CSF is presented.
34. Santiago-Schwarz F, Belilos E, Diamond B, Carsons SE: TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukocyte Biol (1992) 52:274-281. First report on the synergy between GM-CSF and TND in expansion of DC.
35. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature (1992) 360:258-261.
36. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α J Exp Med (1994) 179:1109-1118.
37. Jansen JH, Wientjens GJ, Fibbe WE, Willemze R, Kluin-Nelemans HC: Inhibition of human macrophage colony formation by interleukin 4. J Exp Med (1989) 170:577-582.
38. Borkowski TA, Letterio JJ, Fair AG, Udey MC: A role for endogenous transforming growth factor β1 in Langerhans cell biology: The skin of β1 null mice is devoid of epidermal Langerhans cells. J Exp Med (1996) 184:2417-2422.
39. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K, Majdic O, Knapp W: TGF-β1 promotes In vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol (1996) 157:1499-1507.
40. Riedl E, Strobl H, Majdic O, Knapp W: TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J Immunol (1997) 156:1591-1597.
41. Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G, Gianni AM: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol (1995) 23:463-1471.
42. Maraskowsky E, Roux E, Teepe M, McKenna HJ, Brasel K, Lyman SD, Williams DE: The effect of FIt3 ligand and/or c-Kit ligand on the generation of dendritic cells from human CD34+ bone marrow, Blood (1995) 86:420-427.
43. Szabolcs P, Moore MA, Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-Kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol (1995) 154:5851-5861.
44. Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J: Activation of human dendritic cells through CD40 cross-linking. J Exp Med (1994) 180:1263-1272.
45. Flores-Romo L, Björck P, Ouvert V, van Kooten C, Saeland S, Banchereau J: CD40 ligation on human cord blood CD34+ hematopoietic progenitors Induces their proliferation and differentiation into functional dendritic cells. J Exp Med (1997) 185:341-349.
46. Esche C, Shurin MR, Haluszczak C, Peron JM, Lotze MT: Generation of human dendritic cells from CD34+ precursors for human clinical trials. J Immunother (1997) 20:403a.
47. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell (1991) 65:1143-1152.
48. Rosnet O, Mattei MG, Marchetto S, Birnbaum D: Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics (1991) 9:380-385.
49. Lyman SD, James L, van den Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS. McKenna HJ, Splett RR, Fletcher FF, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP: Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell (1993) 75:1157-1167.
50. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Roncarolo MG, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F: Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature (1994) 368:643-648.
51. Shurin MR, Esche C, Lotze MT: FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev (1998) 9:37-48.
52. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 ligand-treaqted mice: Multiple dendritic cell subpopulations identified. J Exp Med (1996) 184:1953-1962.
53. Shurin MR, Pandharipande PP, Zorina T, Haluszczak C, Subbotin VM, Hunter O, Brurnfield A, Storkus WJ, Maraskovsky E, Lotze MT: FLT3 ligand Induces the generation of functionally active dendritic cells In mice. Cell Immunol (1997) 179:174-184.
54. Esche C, Subbotin VM, Hunter O, Lotze MT, Shurin MR: FLT3 Ligand and Interleukin-12 regulate accumulation of dendritic cells and mast cells In murine skin. Arch Dermatol Res (1998) 290:87a.
55. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL: Flt3 ligand Induces tumor regression and antitumor Immune responses In vivo. Nat Med (1997) 3:625-631. First report on the antitumor effect of FL
56. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cometta K: Antitumor activity and immunotherapeutic properties of flt3-ligand in a murine breast cancer model. Cancer Res (1997) 57:3511-3516.
57. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3 Ligand administration Inhibits tumor growth in murine melanoma and lymphoma. Cancer Res (1998) 58:380-383.
58. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3 ligand administration Inhibits liver metastases: Role of NK cells. J Immunol (1998) 161:6164-6170.
59. Lotze MT: Getting the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg (1997) 226:1-5.
60. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD: DNA-based Immunization by In vivo transfectlon of dendritic cells. Nat Med (1996) 2:1122-1128.
61. Rosenberg SA: Cancer vaccines based on the Identification of genes encoding cancer regression antigens. Immunol Today(1997) 18:175-182.
62. van den Eynde BJ, van der Bruggen P: T-cell defined tumor antigens. Curr Opin Immunol (1997) 9:684-693.
63. Maeurer MJ, Lotze MT: Tumor recognition by the cellular immune system: New aspects of tumor Immunology. Int Rev Immunol (1997) 14:97-132.
64. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van Den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science (1991) 254:1643-1647. Identification of the first TAA.
65. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA: Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res (1993) 53:5-8.
66. Gaugler B, van den Eynde B, van der Gruggen P, Romerao P, Gaforio JJ, de Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. J Exp Med (1994) 179:921 -930.
67. Brichard V, Van Pel A, Wölfel T, De Plaen E, Lethé B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytoiytic T-lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 178:489-495.
68. Robbing PF, El-Gamil M, Kawakami Y, Rosenberg SA: Recognition of tyroslnase by tumor-infiltrating lymphocytes from s patient responding to immunotherapy. Cancer Res (1994) 54:3124-3126.
69. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T: Two tyrosinase nonapeptldes recognized on HLA-A2 melanomas by autologous cytolytic T-lymphocytes. Eur J Immunol (1994) 24:759-764.
70. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells Infiltrating Into tumor. Proc Natl Acad Sci USA (1994) 91:3515-3519.
71. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversarl C, Mattei S, De Plaen E, Lurquin C, Szitora JP: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 180:35-42.
72. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff Jr CL: Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science (1994) 264:716-719.
73. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific gp100 Is recognized by melanoma derived tumor Infiltrating lymphocytes. J Exp Med (1994) 179:1005-1009.
74. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4:321-327.
75. Knight SC, Hunt R, Dore C, Medawar PB: Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA (1985) 82:4495-4497. First report on the use of DC for cancer vaccination.
76. Gyure LA, Barfoot R, Denham S, Hall JG: Immunity to a syngeneic sarcoma induced In rats by dendritic lymph cells exposed to the tumour either In vivo or In vitro. Brit J Cancer (1987) 55:17-20.
77. Shimizu J, Suda T, Yoshioka T, Kosugi A, Fujiwara H, Hamaoka T: Induction of tumor-specific In vivo protective Immunity by Immunization with tumor antigen-pulsed antigen-presenting cells. J Immunol (1989) 142:1053-1059.
78. Shimizu J, Zou JP, Ikegame K, Katagiri T, Fujiwara H, Hamaoko T: Evidence for the functional binding In vivo of tumor rejection antigens to antigen-presenting cells In tumor-bearing hosts. J Immunol (1991) 146:1708-1714.
79. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD: Tumor antigen presentation by murine epidermal cells. J Immunol (1991) 146:3656-3661.
80. Flamand V, Somasse T, Thlelemans K, Demanet C, Bakkus M, Bazin H, Tielemanns F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed In vitro with tumor antigen Induce tumor resistance In vivo. Eur J Immunol (1994) 24:605-610.
81. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent Inducers of cytotoxic T-lymphocytes. J Exp Med (1995) 182:255-260.
82. Ossevoort MA, Fettkamp MCW, van Veen KJH, Melief CJM, Kast WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine In protection against a human papillomavlrus type 16-induced tumor. J Immunother (1995) 18:86-94.
83. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CF, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med (1995) 1:1297-2302.
84. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T-cells, B7 costimuiation, and T-helper cell 1-associated cytoklnes. J Exp Med (1996) 183:87-97.
85. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med (1996) 183:1357-1365.
86. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD: Peptide-puised dendritic cells Induce antigen-specific, CTL-mediated protective tumor Immunity. J Exp Med (1996) 183:283-287.
87. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP: Dendritic cells in antitumor Immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol (1996) 170:111-119.
88. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded In vitro with soluble protein prime cytotoxlc T-lymphocytes against tumor antigen In vivo. J Exp Med (1996) 183:317-322.
89. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol (1996) 156:2918-2926.
90. Boczkowskl D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells In vitro and In vivo. J Exp Med (1996) 184:465-472.
91. Nair SK, Snyder D, Rouse BT, Gilboa E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer (1997) 70:706-715.
92. Nair SK, Boczkowski D, Snyder D, Gilboa E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol (1997) 27:589-597.
93. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts on tumor RNA Induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 186:1177-1182.
94. Okada H, Tahara H, Shurin MR, Attanucci J, Glezeman-Smits KM, Fellows W, Lotze MT, Chambers WH, Bozik ME: Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor Immunity against Intracranial neoplasms. Int J Cancer (1998) 78:196-201.
95. Gong J, Chen D, Kashtwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med (1997) 3:558-561.
96. Lespagnard L, Mettens P, Verheyden AM, Taslaux N, Thielemans K, van Melrvenne S, Geldhof A, de Baetselier P, Urbain J, Leo O, Moser M: Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor Immunity. Int J Cancer (1998) 76:250-258.
97. Celluzzi CM, Falo LD: Physical interaction between dendritic cells and tumor cells results in an immunogen that Induces protective and therapeutic tumor rejection. J Immunol (1998) 160:3081-3085.
98. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med (1998) 4:594-600.
99. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2:52-58.
100. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371-380.
101. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4:328-332.
102. Schuler G, Stelnman RM: Dendritic cells as adjuvants for Immune-mediated resistance to tumors. J Exp Med (1997) 186:1183-1187.
103. Wojtowicz-Praga S: Reversal of tumor-induced Immunosuppression: A new approach to cancer therapy. J Immunother (1997) 20:165-176. Excellent discussion of a new approach for cancer therapy.
104. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol (1996) 170:101-110.
105. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP: Production of vascular endothellal growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 2:1096-1103. The inhibition of DC maturation by VEGF is a potential mechanism of tumor-induced immunosuppression.
106. Gabrilovich DI, Corak J, Ciemik IJ, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res (1997) 3:483-490.
107. Shurin MR, Esche C, Lokshin A, Loize MT: Apoptosis in dendritic cells. In: Dendritic cells. Biology and clinical application (1998), Lotze MT, Thomson AW (Eds), Academic Press, San Diego, 673-692. First report on tumor-induced DC apopiosis.
108. Vujanovic NL, Basse P, Herberman RB, Whiteside TL: Antitumor functions of natural killer cells and control of metastases. In: Methods: A Companion to Methods in Enzymology (1996) 9:394-408.
109. Esche C, Lokshin A, Lotze MT, Shurin MR: Murine and human melanoma Induces apoptosis of dendritic cells: a potential mechanism of tumor-induced immuno suppression. J Invest Dermatol (1998) 110:630a.
110. Esche C, Gambotto A, Robbins P, Watkins SC, Lotze MT, Shurin MR. CD154 (CD40L) expression inhibits tumor growth In an IL-12-dependent fashion and promotes dendritic cell survival. J Immunother (1998) 21:464a.